NEW YORK (GenomeWeb News) – Life sciences company Warnex and microRNA-based molecular diagnostics developer Rosetta Genomics announced today that Warnex Medical Laboratories has signed an exclusive agreement to distribute three of Rosetta's currently available diagnostic tests in Canada.
Under the agreement, Warnex will market the miRview mets test, the miRview squamous test, and the miRview meso test, and it will send Canadian samples to a CLIA-certified lab in Philadelphia for analysis.
All three miRview tests — which test for primary tumor site, squamous versus non-squamous non-small cell lung cancer, and mesothelioma, respectively — were developed by Rosetta based on proprietary miRNA technology and rely on measuring miRNA biomarker expression in tumor samples.
"This agreement joins our existing contracts with Prometheus Laboratories in the US, and with Teva Pharmaceuticals in Israel and Turkey," Rosetta Genomics Chief Commercialization Officer Ronen Tamir said in a statement. "We continue in our efforts to expand our global distribution network to other parts of the world, and expect to have additional agreements in place in the near future."
Financial terms of the agreement were not disclosed.